Last reviewed · How we verify
NCT05529745: NRCEcog
Neurorehabilitation Impact on Neurocognitive Impairments in Cerebellar Lesions
NA trial testing Neurorehabilitation cerebellar cognitive disorder in Cerebellum; Injury in 50 participants. Not yet recruiting.
30 June 2026
Quick facts
| Lead sponsor | Klinik Bavaria |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 June 2023 |
| Primary completion | 30 June 2026 |
| Estimated completion | 31 May 2027 |
Drugs / interventions tested
- Neurorehabilitation cerebellar cognitive disorder
Conditions studied
- Cerebellum; Injury — all drugs for Cerebellum; Injury →
Sponsor
Klinik Bavaria
Who can join
Eligibility, any sex, with Cerebellum; Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Depending on their localization, cerebellar lesions cause various pronounced cognitive and/or affective dysfunctions, which are causally related to the involvement of cerebellar structures in neuronal networks for higher-order processing of cognitive and emotional items in the association areas of the cerebral cortex. For further investigation, event-related potential (ERP) analyses will be performed to record and visualize specific signals in the surface EEG, which should provide information about the course of treatment of neurorehabilitation with respect to a close correlation and thus predictive power to functional recovery that occurred as a result of cerebellar injury. With EEG parameters and clinical examination findings including neuropsychology, the functions for four thematically distributed domains (affective: prosody; cognitive: abstraction, linguistic and formal incongruence) will be recorded and evaluated over a four-week structured neurorehabilitation with an average therapy volume.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05529745
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Klinik Bavaria trials
Trials by the same sponsor.
- NCT05572385 — Clinic and Neurophysiology of Aphasia Treatment · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05529745 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Klinik Bavaria
- Last refreshed: 7 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05529745.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing